Cladribine tablets can improve quality of life in people with highly active relapsing multiple sclerosis (MS), according to recently reported results from the CLARIFY-MS phase II trial. Data from 433 participants who received cladribine for 2 years were included in a mixed-model analysis of MS quality of life (MSQoL)-54 scores. Both MSQoL-54 physical and mental health composite scores significantly improved at 24 months compared with baseline. These results add to the robust safety and efficacy profile of cladribine, which is already approved by the FDA for this indication.